RLYB - Recursion to buy Rallybio's ownership in jointly developed bone disorder drug
2025-07-08 08:39:40 ET
More on Rallybio, Recursion Pharmaceuticals
- Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable
- Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky
- Recursion Pharmaceuticals: High-Risk Play Getting Riskier By The Quarter
- Recursion Pharma to reduce workforce by 20%
- Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 2026